1. Definition of neutropenia

Neutropenia = ANC below the age-appropriate normal lower limit.

In older children/adults, a commonly used cutoff is:

ANC <1,500 cells/µL (1.5 × 10⁹/L)

However, ANC must be interpreted according to age and population, particularly in infants and young children. The infection risk correlates much more strongly with the severity and duration of neutropenia than simply with whether ANC is below 1,500. (MSD Manuals)

For pediatrics, the key is to distinguish neutropenia (a laboratory finding) from febrile neutropenia (a clinical emergency defined by fever + sufficiently low ANC).

Calculate ANC

ANC=WBC×(%neutrophils+%bands)100\boxed{ANC = WBC \times \frac{(\%neutrophils+\%bands)}{100}}

Example:

WBC = 2,000/µL
Neutrophils = 20%
Bands = 5%

ANC = 2,000 × 25/100 = 500/µL

2. Classification by ANC

These are the conventional severity categories used clinically. (MSD Manuals)

Important threshold

ANC <500/µL = severe neutropenia.

At this level, organisms from the patient’s own oral/GI flora can produce serious infection. At ANC <200/µL, signs of inflammation can be particularly muted. (MSD Manuals)

3. Classification by duration

Acute neutropenia

Develops over hours to days.

Common causes:

• Viral infection
• Drugs
• Chemotherapy
• Severe bacterial infection/sepsis
• Acute marrow suppression

Chronic neutropenia

Persists for months or longer.

Examples:

• Chronic benign/idiopathic neutropenia
• Autoimmune neutropenia
• Congenital neutropenia
• Cyclic neutropenia
• Bone marrow disorders

4. Classification by mechanism

A. Decreased production

• Chemotherapy/radiation
• Aplastic anemia
• Leukemia/marrow infiltration
• Myelodysplasia
• B12/folate deficiency
• Severe malnutrition
• Congenital neutropenia

B. Increased destruction/consumption

• Autoimmune neutropenia
• Drug-induced immune neutropenia
• Severe infections/sepsis

C. Sequestration

• Hypersplenism

There can also be mixed mechanisms. (MSD Manuals)

5. What exactly is febrile neutropenia?

The classic oncology definition is:

Fever

Either:

• Single temperature ≥38.3°C, OR
• ≥38.0°C sustained for ≥1 hour

AND

Neutropenia

• ANC <500/µL, OR
• ANC expected to fall to <500/µL within the next 48 hours

(IDMP)

So:

Fever + ANC <500 = febrile neutropenia until proven otherwise.

This is particularly important in children receiving chemotherapy or hematopoietic stem-cell transplantation.

6. What is NOT necessarily called febrile neutropenia?

This is an important distinction.

Scenario 1 — Fever + ANC 800

Not conventionally called febrile neutropenia because ANC is >500.

But the child has:

Fever with moderate neutropenia

The clinical approach depends heavily on the underlying disease and immune status.

Scenario 2 — Fever + ANC 1,200

Not febrile neutropenia.

It’s simply:

Fever with mild neutropenia

Look for an underlying viral illness, drug effect, etc.

Scenario 3 — ANC <500 but NO fever

This is:

Severe/profound afebrile neutropenia

Not febrile neutropenia.

However, it may still require urgent assessment depending on the cause, duration and clinical condition.

Scenario 4 — Fever + transient viral neutropenia in an otherwise well child

For example:

4-year-old with viral URI
Temperature 39°C
ANC 700
Otherwise well

This is febrile illness with moderate neutropenia, not classic febrile neutropenia.

You shouldn’t automatically apply the chemotherapy febrile-neutropenia pathway simply because the child happens to have a low ANC.

7. The important pediatric exception

This is where clinicians sometimes get confused.

A child with:

fever + ANC <500

may technically fulfill the numerical definition of febrile neutropenia.

But management depends on the clinical context.

For example:

Child receiving chemotherapy

Fever + ANC <500
→ Treat as febrile neutropenia
→ urgent cultures + empiric antipseudomonal antibiotic.

Previously healthy child with viral illness

Fever + ANC <500
→ technically febrile severe neutropenia, but this is not automatically equivalent to chemotherapy-associated febrile neutropenia.

The risk profile is different.

8. Conditions where you should NOT casually label it “febrile neutropenia”

Think of these separately:

The distinction matters because chemotherapy-associated febrile neutropenia is a high-risk infectious syndrome, whereas many otherwise healthy children develop transient neutropenia during viral infections.

9. Management of neutropenia

A. First question: Is the child febrile or clinically unwell?

If fever + severe neutropenia

Treat as a potentially serious infection.

Immediate:

1. ABC/clinical stability
2. Full examination
3. CBC + differential
4. Blood cultures
5. Urine evaluation/culture when appropriate
6. Evaluate for focal infection
7. Start appropriate empiric antibiotics promptly

For high-risk pediatric oncology patients, institutional protocols commonly use an antipseudomonal β-lactam such as cefepime, with escalation/additional coverage based on instability, focal infection, resistant organisms and local epidemiology. (IDMP)

Do not wait for the ANC to recover before treating a clinically significant suspected infection.

10. If the child is afebrile

Management depends on:

• ANC
• Duration of neutropenia
• Age
• Previous infections
• Underlying disease
• Chemotherapy/HSCT status
• Medications
• Clinical appearance

Mild ANC 1,000–1,500

Usually:

Observe + repeat CBC + investigate cause if persistent.

Moderate ANC 500–1,000

Look for cause and follow trend.

Severe ANC <500

Need much closer assessment, particularly if persistent.

Profound ANC <200

Highest concern for serious infection; clinical signs may be deceptively subtle. (MSD Manuals)

11. Treat the cause

Examples:

Drug-induced
→ stop suspected offending drug when appropriate.

Viral
→ usually supportive treatment and serial ANC.

Autoimmune neutropenia
→ often observation if child is clinically well; treatment depends on severity/infections.

Congenital/severe chronic neutropenia
→ hematology evaluation; G-CSF may be indicated.

Chemotherapy-induced
→ oncology-directed management ± G-CSF depending on regimen/risk.

Nutritional
→ correct B12/folate/nutritional deficiency.

Bone marrow failure/infiltration
→ urgent hematology evaluation.

G-CSF is particularly useful in selected severe/chronic neutropenia and in prevention/reduction of chemotherapy-related neutropenia. (MSD Manuals)

High-yield exam summary

Neutropenia = low ANC.

ANC:

• 1000–1500 → mild
• 500–1000 → moderate
• <500 → severe
• <200 → profound

Febrile neutropenia:

Fever ≥38.3°C once OR ≥38.0°C for ≥1 h + ANC <500/µL (or expected to fall <500 within 48 h).

And remember:

ANC <500 without fever = severe neutropenia, NOT febrile neutropenia.

Fever with ANC 500–1000 = febrile illness with moderate neutropenia, not the conventional febrile-neutropenia definition.

The classic “febrile neutropenia” pathway is particularly relevant to children receiving chemotherapy/HSCT; don’t automatically equate every viral-associated neutropenia in a healthy child with chemotherapy-associated FN. (IDMP)

Vitamin-responsive seizures are uncommon, but they represent some of the most important treatable causes of neonatal and early-infantile epilepsy. Recognizing them early can prevent status epilepticus, developmental injury, and potentially irreversible neurological damage.

Introduction

Neonatal seizures are usually approached as an emergency, with hypoxic-ischemic injury, hypoglycemia, hypocalcemia, intracranial hemorrhage, stroke, infection, and structural brain abnormalities among the major considerations.

However, a small but particularly important group of seizures results from inborn errors of metabolism involving vitamins or vitamin-dependent enzymes. These seizures may be remarkably resistant to conventional antiseizure medications but respond dramatically to administration of the appropriate vitamin or cofactor.

The major clinically relevant disorders include:

• Pyridoxine-dependent epilepsy (PDE)
• Pyridoxal-5′-phosphate (PLP)-dependent epilepsy
• Folinic acid-responsive seizures
• Biotinidase deficiency
• Biotin-thiamine-responsive basal ganglia disease
• Other metabolic disorders in which vitamin/cofactor therapy can be seizure-modifying

Among these, vitamin B6-dependent epilepsies are particularly important in the neonate.

1. When should you suspect a vitamin-responsive seizure disorder?

The diagnosis should enter the differential particularly when a neonate or infant has:

Red flags

1. Seizures beginning in the neonatal period without an obvious cause
2. Frequent or recurrent seizures despite appropriate antiseizure medication
3. Status epilepticus
4. Abnormal EEG with burst suppression or marked discontinuity
5. Seizures accompanied by unexplained encephalopathy
6. Irritability, abnormal crying, vomiting, or feeding difficulty
7. Unexplained metabolic acidosis or elevated lactate
8. Seizures recurring after apparently successful treatment
9. A previous sibling who died from unexplained neonatal seizures
10. Consanguinity or a family history suggestive of an autosomal-recessive disorder
11. Seizures with unusual movements, spasms, myoclonus, or autonomic features
12. Seizures that respond dramatically to pyridoxine or PLP

The ILAE specifically recommends considering a trial of pyridoxine in neonates with clinical features suggestive of vitamin B6-dependent epilepsy and in neonates whose seizures remain unexplained and refractory to second-line antiseizure medication.

2. Pyridoxine-dependent epilepsy

The classic vitamin-responsive epilepsy

Pyridoxine-dependent epilepsy is one of the most important treatable causes of neonatal-onset epilepsy.

The classical form is caused by pathogenic variants in ALDH7A1, which encodes antiquitin, an enzyme involved in lysine degradation. Deficiency results in accumulation of metabolites including α-aminoadipic semialdehyde (α-AASA)/P6C. P6C can inactivate pyridoxal-5′-phosphate (PLP), ultimately impairing neurotransmitter synthesis and producing seizures.

Clinical presentation

The classical presentation is:

A neonate with otherwise unexplained, frequent, treatment-resistant seizures.

Seizures may be:

• Focal
• Multifocal
• Generalized
• Clonic
• Tonic
• Myoclonic
• Epileptic spasms

Some infants may initially appear encephalopathic rather than having obvious convulsive seizures.

The ILAE recognizes frequent drug-resistant seizures, often progressing to status epilepticus, with marked reduction or cessation following pyridoxine supplementation as characteristic of vitamin B6-dependent epilepsy.

An important clue

Some infants may have:

• Irritability
• Restlessness
• Abnormal crying
• Vomiting
• Feeding difficulties

before or around the time of seizures.

3. Why does pyridoxine stop the seizure?

Vitamin B6 exists in several biologically active forms. Pyridoxal-5′-phosphate (PLP) is the major active cofactor involved in numerous enzymatic reactions.

One of its critical neurological roles is participation in neurotransmitter synthesis.

In pyridoxine-dependent epilepsy, abnormal lysine metabolism leads to accumulation of metabolites that interfere with PLP availability.

Therefore:

ALDH7A1 defect

↓

Abnormal lysine degradation

↓

↑ α-AASA/P6C

↓

PLP inactivation

↓

Impaired neurotransmitter synthesis

↓

Neuronal hyperexcitability

↓

Seizures

Administration of pharmacological doses of pyridoxine restores adequate PLP availability and suppresses seizures.

4. Pyridoxine trial

This is one of the most important practical points in neonatal neurology.

A pyridoxine trial should be performed under continuous cardiorespiratory and preferably EEG monitoring, because intravenous pyridoxine can cause significant apnea, respiratory depression, and prolonged somnolence.

For prolonged/refractory clinical seizures, a commonly used approach is:

Pyridoxine 100 mg IV, with EEG and cardiorespiratory monitoring.

If there is no response, further doses may be administered according to specialist/neonatal protocol, with some references allowing repeated dosing up to a cumulative 500 mg.

The ILAE notes that responses can occasionally be delayed; therefore, lack of an immediate response does not automatically exclude vitamin B6-dependent epilepsy. A trial may need to be continued for several days in selected patients.

Important safety point

Do not give a high-dose IV pyridoxine trial to an unsupervised neonate.

Apnea and cardiorespiratory depression can occur, so airway and ventilatory support must be immediately available.

5. Pyridoxine maintenance therapy

Once pyridoxine-dependent epilepsy is established, treatment is generally lifelong.

Current International PDE Consortium recommendations summarized by GeneReviews include:

Doses should be individualized by a metabolic/pediatric neurology team.

Long-term excessive pyridoxine can produce sensory neuropathy, so high-dose therapy requires monitoring.

6. Pyridoxal-5′-phosphate-dependent epilepsy

Not every vitamin B6-responsive seizure disorder responds to pyridoxine itself.

This distinction is crucial.

Pyridoxamine-5′-phosphate oxidase (PNPO) deficiency results from pathogenic variants in PNPO.

The enzyme is required for conversion of pyridoxine/pyridoxamine derivatives to the active cofactor PLP.

Therefore:

Pyridoxine → requires metabolic activation → PLP

If this pathway is defective, administering pyridoxine may not adequately correct the biochemical defect.

These patients may instead respond to pyridoxal-5′-phosphate (PLP).

Practical distinction

The ILAE recognizes ALDH7A1, PNPO and PLPBP-related disorders among the genetic causes of vitamin B6-dependent epilepsy.

7. PLPBP deficiency

PLPBP encodes pyridoxal phosphate-binding protein.

Deficiency can produce neonatal or infantile epilepsy with variable response to pyridoxine or PLP.

This disorder highlights an important clinical principle:

A negative response to one form of vitamin B6 does not necessarily exclude a vitamin B6-dependent epilepsy.

Patients may require a carefully monitored trial of the appropriate B6 formulation under metabolic/neurology supervision.

8. Folinic acid-responsive seizures

Another important treatable cause is folinic acid-responsive epilepsy.

These infants can present with:

• Neonatal seizures
• Drug-resistant epilepsy
• Encephalopathy
• Abnormal EEG
• Sometimes a transient or incomplete response to pyridoxine

An important clinical clue is:

Seizures initially improve with pyridoxine but subsequently recur.

Folinic acid may then produce seizure control.

Interestingly, subsequent biochemical and genetic work demonstrated substantial overlap between classical folinic acid-responsive seizures and ALDH7A1-related pyridoxine-dependent epilepsy.

Thus, the old concept of completely separate “pyridoxine-responsive” and “folinic-acid-responsive” disorders has become more nuanced.

9. When should folinic acid be considered?

Folinic acid should be considered particularly when:

• Neonatal seizures are unexplained
• Pyridoxine produces only a partial/transient response
• Seizures recur despite pyridoxine
• There is biochemical/genetic evidence suggesting a folate-related disorder

Some literature describes folinic acid doses in the range of approximately 3–5 mg/kg/day, but dosing should be directed by a pediatric neurologist/metabolic specialist because the optimal regimen depends on the suspected disorder.

10. Biotin-responsive seizures

Biotinidase deficiency is another important treatable metabolic disorder.

Biotinidase is responsible for recycling biotin, an essential cofactor for several carboxylases.

Untreated profound biotinidase deficiency can produce:

• Seizures
• Hypotonia
• Developmental delay
• Ataxia
• Alopecia
• Eczematous rash
• Conjunctivitis
• Hearing loss
• Optic atrophy
• Respiratory abnormalities

Seizures may be focal, generalized, or myoclonic, and infantile spasms have also been reported.

The key point

This is a highly treatable disorder.

Early treatment can prevent neurological injury, and seizures can resolve rapidly after biotin supplementation.

11. Biotinidase deficiency: treatment

Current GeneReviews recommendations are:

• Profound deficiency: oral biotin 5–10 mg/day
• Partial deficiency: approximately 2.5–10 mg/day

Treatment is generally lifelong.

An important practical issue is that biotin can interfere with certain laboratory immunoassays, potentially producing misleading results. Clinicians should inform the laboratory when a patient is receiving pharmacological doses of biotin.

12. Biotin-thiamine-responsive basal ganglia disease

This is a particularly fascinating vitamin-responsive neurological disorder.

It results from pathogenic variants in SLC19A3, which encodes thiamine transporter 2.

It can present in three broad patterns:

Early-infantile disease

Usually before 3 months of age:

• Vomiting
• Feeding difficulty
• Encephalopathy
• Hypotonia
• Seizures/infantile spasms
• Respiratory failure
• Severe lactic acidosis

Childhood disease

Usually presents with recurrent episodes of:

• Encephalopathy
• Seizures
• Ataxia
• Dystonia
• Ophthalmoplegia
• Dysphagia

Episodes may be precipitated by febrile illness or metabolic stress.

MRI clue

Symmetrical abnormalities involving the:

• Caudate
• Putamen
• Medial thalami

with possible extension to the brainstem and other structures should raise suspicion.

13. Treatment of biotin-thiamine-responsive basal ganglia disease

Treatment should be started promptly when the disorder is suspected.

GeneReviews recommends:

Biotin: 5–10 mg/kg/day

plus

Thiamine: up to 40 mg/kg/day, maximum 1,500 mg/day

with lifelong therapy. During acute decompensation, thiamine may be increased and administered intravenously.

Early treatment is critical because neurological damage may become irreversible.

14. Other metabolic disorders where vitamins matter

Vitamin-responsive seizures should not be interpreted as only a “B6 problem.”

Other treatable metabolic epilepsies include disorders involving:

• Folate metabolism
• Thiamine metabolism
• Biotin metabolism
• Riboflavin-related pathways
• Vitamin B12/cobalamin metabolism
• Serine synthesis
• Creatine metabolism
• Glucose transport
• Mitochondrial metabolism

Some are better classified as cofactor-responsive metabolic epilepsies rather than classical vitamin-dependent epilepsy.

A broad metabolic approach is therefore essential in unexplained refractory neonatal epilepsy. Reviews of inborn errors of metabolism in pediatric epilepsy emphasize pyridoxine/PLP, folinic acid and biotin among the particularly important treatable pathways.

15. Practical approach to a neonate with refractory seizures

A useful bedside approach is:

Step 1 — Stabilize

ABC + glucose

Check:

• Blood glucose
• Calcium
• Magnesium
• Sodium
• Potassium
• Blood gas
• Lactate

Treat immediately reversible abnormalities.

Step 2 — Search for common causes

Consider:

• HIE
• Intracranial hemorrhage
• Stroke
• CNS infection
• Hypoglycemia
• Hypocalcemia
• Electrolyte abnormalities
• Structural brain disease

Step 3 — EEG

Use continuous EEG where available.

Vitamin-dependent epilepsies can have distinctive EEG abnormalities, including burst suppression or marked discontinuity, although these findings are not diagnostic by themselves.

Step 4 — If seizures remain unexplained/refractory

Think:

“Could this be a vitamin-dependent epilepsy?”

Step 5 — Consider a monitored pyridoxine trial

Especially when:

• Etiology remains unexplained
• Seizures are refractory
• Clinical/EEG findings suggest B6-dependent epilepsy

This approach is supported by current ILAE neonatal seizure recommendations.

Step 6 — If pyridoxine fails

Consider:

PLP-dependent epilepsy → pyridoxal-5′-phosphate

and

Folinic-acid responsive epilepsy → folinic acid

under specialist guidance.

Step 7 — Send metabolic/genetic testing

Depending on availability:

• Urine/plasma α-AASA
• Pipecolic acid
• PLP-related studies
• Biotinidase activity
• Lactate
• Ammonia
• Plasma amino acids
• Acylcarnitine profile
• Urine organic acids
• CSF studies when indicated
• Epilepsy/metabolic gene panel
• Whole-exome/genome sequencing

Importantly, treatment should not necessarily be delayed until genetic confirmation when clinical suspicion is high.

16. High-yield comparison

17. The most important neonatal pearl

A neonate with refractory seizures of unexplained etiology should trigger consideration of pyridoxine-dependent epilepsy.

The important sequence is:

Unexplained neonatal seizures

↓

Correct glucose/electrolytes + evaluate structural/infectious causes

↓

Persistent/refractory seizures

↓

Consider vitamin B6-dependent epilepsy

↓

Monitored pyridoxine trial

↓

If inadequate response → consider PLP

↓

Consider folinic acid and other metabolic/cofactor-responsive disorders

↓

Confirm with biochemical/genetic testing

This is particularly important because the treatment is relatively simple compared with the potential consequences of missing the diagnosis. The ILAE specifically recommends a pyridoxine trial in selected neonates with unexplained refractory seizures.

18. Take-home points

1. Vitamin-responsive epilepsies are rare but potentially dramatically treatable causes of neonatal and infantile seizures.
2. Pyridoxine-dependent epilepsy is the classic disorder to remember.
3. ALDH7A1/antiquitin deficiency is the major cause of classical pyridoxine-dependent epilepsy.
4. PNPO deficiency may respond to PLP rather than pyridoxine.
5. A transient or incomplete pyridoxine response should not end the investigation.
6. Folinic acid-responsive seizures should be considered in selected refractory cases.
7. Biotinidase deficiency can cause seizures, hypotonia, rash, alopecia, and developmental problems—and is highly treatable.
8. SLC19A3-related biotin-thiamine-responsive basal ganglia disease is another important treatable disorder, particularly when encephalopathy, lactic acidosis and basal ganglia MRI abnormalities coexist.
9. High-dose IV pyridoxine can cause apnea and cardiorespiratory depression; administration requires appropriate monitoring and resuscitation capability.
10. Do not wait for genetic confirmation before treating a strongly suspected vitamin-dependent epilepsy.

References

Major pediatric/neonatal textbooks

1. Kliegman RM, St Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 22nd ed. Elsevier; 2023. Sections on neonatal seizures, epilepsy, and inborn errors of metabolism.
2. Eichenwald EC, Hansen AR, Martin CR, Stark AR, eds. Cloherty and Stark’s Manual of Neonatal Care. 9th ed. Wolters Kluwer; 2022. Sections on neonatal seizures and metabolic disorders.
3. Gleason CA, Juul SE, eds. Avery’s Diseases of the Newborn. 11th ed. Elsevier; 2024. Sections on neonatal neurologic disorders, seizures, and inborn errors of metabolism.
4. Volpe JJ. Volpe’s Neurology of the Newborn. 7th ed. Elsevier; 2018. Chapters on neonatal seizures and metabolic/epileptic disorders.

Guidelines and primary/review literature

5. Pressler RM, Cilio MR, Mizrahi EM, et al. Treatment of seizures in the neonate: Guidelines and consensus-based recommendations—Special report from the ILAE Task Force on Neonatal Seizures. Epilepsia. 2023.
6. Stockler S, Plecko B, Gospe SM Jr, et al. Neonatal vitamin-responsive epileptic encephalopathies. Neuropediatrics. 2011.
7. Coughlin CR, Tseng LA, et al. International consensus recommendations for the diagnosis and management of pyridoxine-dependent epilepsy. 2021.
8. GeneReviews. Pyridoxine-Dependent Epilepsy – ALDH7A1. University of Washington, Seattle. Updated 2026.
9. GeneReviews. Biotinidase Deficiency. University of Washington, Seattle. Updated 2026.
10. GeneReviews. Biotin-Thiamine-Responsive Basal Ganglia Disease. University of Washington, Seattle. Updated 2025.
11. Gallagher RC, Van Hove JLK, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol. 2009;65(5):550-556.
12. Inborn Errors of Metabolism in Pediatric Epilepsy. Pediatr Neurol. Review of vitamin/cofactor-responsive epilepsies.
13. ILAE Task Force. Classification and diagnostic criteria for early-onset vitamin-dependent developmental and epileptic encephalopathies.

Editorial note

For a medical blog, I would not present the dosing section as a general prescription protocol. High-dose pyridoxine and PLP trials—particularly IV administration in neonates—should be performed in a monitored setting with respiratory support available. The exact treatment protocol should follow the neonatal unit’s guideline and pediatric neurology/metabolic specialist recommendations. The ILAE evidence base also acknowledges that much of the evidence for neonatal pyridoxine/PLP therapy is retrospective rather than from randomized trials.